Medication Treatment for Tics and Tourette’s

There are several kinds of medication than can help kids with Tourette’s or another tic disorder. But it’s important to note that not all kids who develop tics need treatment. Tics are very common. They often go away on their own, and they tend to bother parents more than they do the children experiencing them. Drawing attention to them can make them worse. So doing nothing can be the best strategy — at least initially.

Treatment comes into play if tics are upsetting your child, giving them pain, or making it hard for them to function in everyday life — say they’re disrupting class or getting bullied because of their tics.

The first recommended step in treatment is a specialized form of therapy called comprehensive behavioral intervention for tics (CBIT). CBIT is centered on habit reversal training, in which the child learns to recognize when they have an urge to tic and substitute a competing response — an easier, more comfortable, or less noticeable action or behavior that makes the tic impossible. For instance, if a child’s tic is jerking their head to the side, the strategy might be to put their chin down instead.

But if therapy isn’t effective in reducing a child’s tics, medication can help.

Guanfacine and clonidine for tics

First-line medications for Tourette’s and other tic disorders are a class of drugs called alpha-2 agonists, explains Paul Mitrani, MD, PhD, a child and adolescent psychiatrist at the Child Mind Institute. Alpha agonists decrease the release of a neurotransmitter called norepinephrine, which stimulates the nervous system. Alpha agonists serve as a kind of dimmer switch — by calming down the system, they make the urge to tic less frequent, less intense, and by extension, easier to control.

The two alpha-2 agonists usually prescribed for tics are guanfacine and clonidine. Dr. Mitrani reports that he usually starts by prescribing guanfacine because it comes in a longer-acting form (Intuniv), which reduces symptoms for a full 24 hours. Clonidine’s long-acting form (Kapvay) is effective for 12 hours.

Dr. Mitrani adds that there is a new liquid form of clonidine called Onyda XR that lasts 24 hours, but there isn’t yet a strong body of evidence regarding its effectiveness for tics. Onyda XR is FDA-approved for ADHD, as are Kapvay and Intuniv.

While no alpha agonist medications are FDA-approved specifically for tics, Kapvay and Intuniv are frequently used off-label for them. There is ample research on their effectiveness for tics, and they are recommended by clinical practice guidelines.

Some children respond better to several doses of short-acting guanfacine or clonidine, Dr. Mitrani notes, rather than a smoother dose of a long-acting medication. This may be because medication can be timed to peak at times when kids need tic suppression most, such as at school.

Alpha agonists are the preferred first line medications for tic disorders because their side-effects, including drowsiness and low blood pressure, are relatively mild.

Antipsychotics for tics

If alpha agonists aren’t helping, the next step would be to try an antipsychotic medication, which can be more effective for treating tics, Dr. Mitrani notes, but their side effects are potentially more difficult to tolerate.

Aripiprazole (Abilify), which is FDA-approved for tics, is often Dr. Mitrani’s first choice among the antipsychotic medications. Abilify is a second-generation, or atypical, antipsychotic, a group of medications that have fewer side effects than older antipsychotics. Side effects of Abilify can include restlessness, agitation and weight gain.

Haloperidol (Haldol) is also effective for tics, but it’s an older antipsychotic with more side effect concerns, Dr. Mitrani notes. “I’ve only had one patient ever on Haldol, and he tolerated it well and it really helped with his tics when other things did not.”

Risperidone (Risperdal) is another atypical antipsychotic that can help, but its side effects tend to be worse than Abilify. Risperidone can cause more concerning weight gain and metabolic, neurological, and hormonal changes that can be harmful. Sometimes other medications are used to manage the weight gain from antipsychotics.

When kids with tics also have ADHD

More than three-quarters of kids diagnosed with a tic disorder also have another disorder. When a child has multiple disorders, a clinician will want to evaluate which is causing the child the most difficulty and prioritize treating that.

The most common co-occurring disorder with tics is ADHD. “If tics are the bigger problem, we would start with treating them,” says Dr. Mitrani. “If the ADHD is the bigger problem, which it typically is, we usually treat that first.”

In the past, it was recommended that children with tics and ADHD avoid stimulant medication, based on research that showed it made tics worse. But newer studies counter that finding, Dr. Mitrani notes, concluding that the old research was based on very high doses of amphetamine-based medications. To lower the risk of exacerbating tics, he recommends starting kids with ADHD and tics on methylphenidate-based medication.

“If your child is starting a stimulant,” he adds, “and you see worsening of tics — and it’s clearly related to when the stimulant is in their system — the best approach might be a lower dose of stimulant combined with guanfacine or clonidine.”

One advantage to that combination, he notes, is that kids with ADHD who have behavior problems can benefit from the guanfacine or clonidine being active in the mornings before the stimulant starts working and in the evenings when it’s out of their system.

Kids with other co-occurring disorders

When children with tics have other co-occurring disorders, such as anxiety, OCD, or depression, treating them with medication needs to be done very carefully, Dr. Mitrani says. Since children are typically not bothered by the tics themselves, it’s almost always the other disorder that is more problematic for them.  And, he adds, when the other problems cause distress, it can make the tics worse.

For anxiety, OCD, and depression, the first-line medication treatment is an antidepressant. Antidepressants can actually help alleviate tics indirectly, since they reduce anxiety. “Stress increases tics, so if there is significant anxiety and you treat the anxiety, the tics may get better,” Dr. Mitrani says. “And then maybe you don’t need the guanfacine or clonidine. But again, it depends on what the co-occurring disorders are and what’s the bigger problem for the child.”

Monitoring medication for tics

Due to the waxing and waning nature of tics, it can be challenging to see the full effect of medication and other interventions. It is important to give medication enough time to work, Dr. Mitrani notes, typically a few weeks, to see if the overall pattern, frequency, and severity of tics has improved. And children who are being treated should continue to be monitored regularly for any changes, as tics can recur or worsen, especially when a child is excited, tired, or experiencing more stress.

Most children with tics see a natural improvement or even resolution of tics as they progress through adolescence. If there seems to be a long-standing improvement, it is appropriate to consider reducing or stopping medication, especially if the child is experiencing side effects, Dr. Mitrani notes. If tics continue and are causing distress, it is important to keep treating them.

A child going off any of these medications — alpha agonists or antipsychotics — should do so gradually, by having their dose reduced over weeks or even longer, to avoid unpleasant or dangerous side effects of sudden withdrawal.

The post Medication Treatment for Tics and Tourette’s appeared first on Child Mind Institute.

Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Thomas Goetz. Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: Whether it’s Ambien or Wegovy, ivermectin or fluoride, every drug in your medicine cabinet or advertised on TV has a story behind it. Not just how it came to be, but how it ends up affecting society in unexpected ways, big or small.

Read the rest…

New Low-Toxicity Transplant Method Reverses Type 1 Diabetes in Mice

Researchers at Stanford Medicine say they have developed a combination treatment method that cured or prevented type 1 diabetes in mouse models by pairing blood stem cell transplantation with pancreatic islet cell transplantation under a substantially reduced preconditioning regimen. The approach creates a mixed immune system from both donor and recipient cells, which stopped autoimmune destruction of insulin-producing cells while also producing long-term tolerance to the transplanted tissue. The findings, published in the Journal of Clinical Investigation Insight, show that reversing type 1 diabetes can be accomplished without chronic immunosuppression or the toxic conditioning via radiation or chemotherapy currently used for hematopoietic stem cell (HCT) transplantation.

“The possibility of translating these findings into humans is very exciting,” said senior author Seung K. Kim, MD, PhD, a professor of developmental biology at Stanford. “The key steps in our study—which result in animals with a hybrid immune system containing cells from both the donor and the recipient—are already being used in the clinic for other conditions. We believe this approach will be transformative for people with type 1 diabetes or other autoimmune diseases, as well as for those who need solid organ transplants.”

Type 1 diabetes is an autoimmune disease that attacks pancreatic islet cells. While islet transplantation can restore insulin production, it typically requires immunosuppressive drugs that carry risks including infection, malignancy, and organ damage. The Stanford team’s approach reduced these negative effects by inducing immune tolerance through mixed hematopoietic chimerism, a state in which donor and recipient immune cells coexist.

“Mixed hematopoietic chimerism after hematopoietic cell transplantation (HCT) can modulate the immune system and induce tolerance to allogeneic tissues,” the researchers wrote. “However, bone marrow conditioning-related toxicities preclude wider adoption of HCT for transplant allotolerance.”

The current findings by the Stanford team builds on a series of research initiatives beginning with work published in 2022, in which the researchers showed they could cure toxin-induced diabetes in mouse models using antibody-based immune conditioning combined with moderate radiation (200–300 cGy), followed by transplantation of donor-matched blood stem cells and islets. This study served as a proof of concept but used radiation at levels that are potentially toxic.

A November study published in JCI, along with the new research addressed two significant challenges for developing an effective transplantation protocol: autoimmune diabetes, in which the immune system targets islet cells, and the need to reduce conditioning toxicity. In the November study, the researchers added an immune-modulating drug used in autoimmune disease to their regimen. This change enabled the formation of a hybrid immune system that both accepted donor islets and prevented autoimmune attack. All treated mice were protected from developing diabetes, and those with already possessing the disease were cured.

To further reduce toxicity, the April study added additional agents, baricitinib, venetoclax, and an αCD47 antibody, to go with αCD117 antibody and transient T cell depletion. These agents were selected because they target distinct biological pathways involved in immune regulation and bone marrow niche clearance. Baricitinib, a JAK1/2 inhibitor, reduces inflammatory signaling and supports donor cell engraftment. Venetoclax promotes apoptosis of specific immune cells, and αCD47 disrupts a signaling pathway that normally protects cells from clearance, which helped in the removal of host stem cells to make space for donor cells.

“We systematically tested baricitinib (JAK1/2 inhibitor), venetoclax (Bcl2 inhibitor), and αCD47 antibody, agents in current clinical use, and quantified hematopoietic chimerism after HCT,” the researchers wrote. “Combined with αCD117 antibody, transient T cell depletion, and just 10 centigray (cGy) total body irradiation (TBI), these agents enabled durable mixed chimerism and matching allo-islet tolerance, to cure diabetes without evidence of [graft-versus-host disease].”

This new combination allowed researchers to reduce radiation exposure to 10 cGy, a fraction of the levels used in conventional bone marrow transplantation. Mice treated using this regimen showed stable engraftment of donor cells, maintained fertility, and experienced no graft-versus-host disease. They also remained insulin-independent for the duration of the study.

The findings provide a potential pathway toward clinical adoption, which could be speedier than usual since many of the agents used for this approach are already approved or under evaluation in humans.

Work at Stanford will continue in this area and will focus on testing the reduced-intensity regimen in autoimmune diabetes models, refining conditioning strategies, and exploring alternative sources of islet cells, including those derived from stem cells.

If successfully, translated to the clinic, this treatment regimen could reduce or eliminate the need for lifelong insulin therapy, while expanding the use of transplantation-based therapies across a wider set of patients.

The post New Low-Toxicity Transplant Method Reverses Type 1 Diabetes in Mice appeared first on Inside Precision Medicine.

Optimizing Navigation and Text Messaging Interventions to Promote Participation in a Food Is Medicine Program Among People Participating in Cardiac Rehabilitation: Human-Centered Design Study

Background: Food Is Medicine (FIM) programs integrate interventions such as medically tailored meals or produce prescriptions into clinical care. However, there is limited evidence on how to design these programs to be responsive to the lived experiences of participants to optimize initiation, engagement, and long-term retention. Objective: The objective of the study was to develop interventions to promote initiation, engagement, and retention in FIM programs that are responsive to the lived experiences of participants. Methods: We used a human-centered design approach to engage current and former cardiac rehabilitation participants in the development of interventions to promote participation and engagement in a FIM program. We recruited participants through invitations sent via electronic health record messages. We interviewed participants about their experiences, preferences, and unmet needs related to healthy eating and program design. Additionally, we elicited participant feedback on draft versions of patient navigator scripts and text messages promoting healthy eating habits. Results: A total of six participants identified themes across Theory of Planned Behavior constructs and emergent themes, including the cost of healthy food, cultural appropriateness, clear and timely communication, transportation, local food access, scheduling flexibility, the ability to provide feedback to the program, and personalized support for navigating food resources. Participants described financial strain as a key barrier to healthy eating and noted that social influence often shaped eating behaviors. Feedback on navigator scripts led to revisions clarifying program logistics, addressing barriers such as language and cultural dietary restrictions, and tailoring positive endorsements to individual health goals. Based on participant feedback, text messages were made more concise, reframed positively (eg, humor and gratitude), and encouraged to be warmer, with respectful language that is easy to understand, while avoiding stigmatizing or overly clinical phrasing. Participants also suggested that messages should reflect empathy and offer actionable information to increase trust and engagement with the program. Trust in the health care system and a sense of dignity in receiving food support emerged as critical themes influencing overall satisfaction and retention. Participants emphasized that endorsement from their health care team and cardiologist was important for building trust in the program. Communication between health care navigators and FIM navigators could help reduce the burden placed on patients to navigate food resources. Conclusions: Using a human-centered design approach, we gained insights about participant-identified needs for navigation scripts and text messages that are culturally sensitive and personalized to promote optimal participation in a FIM program.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/106004753afe04c792ee781fb8a4c2ba" />

STAT+: FDA to speed up review of three psychedelics as mental health treatments

The Food and Drug Administration will accelerate its review of psychedelic drugs developed by Compass Pathways, the Usona Institute, and Transcend Therapeutics for mental health disorders, as part of the Trump administration’s plan to boost access to the controversial yet promising medications.

The agency will grant priority review vouchers specifically to Compass’ psilocybin product for treatment-resistant depression, Usona’s similar medicine for major depressive disorder, and an MDMA-like treatment for post-traumatic stress disorder from Transcend. 

The FDA identified the medications receiving the vouchers, but not the companies developing them. Compass, Usona, and Transcend confirmed they received vouchers.

Continue to STAT+ to read the full story…

Fibroblast Subset Directs Immune Cell Positioning in Lymph Nodes

Researchers at the University of Lausanne have identified a specialized fibroblast population that actively organizes immune cell interactions within lymph nodes, revealing a key mechanism underlying effective T cell responses to infection and cancer.

The study, published in Immunity, shows that stromal cells, long considered primarily structural, play a central role in orchestrating where and how immune cells meet, with direct consequences for immune activation and memory formation.

Spatial organization drives immune efficiency

Lymph nodes act as surveillance hubs of the immune system, filtering lymphatic fluid and coordinating responses to pathogens or tumor cells. Within these small, highly organized structures, immune cells are not randomly distributed. Instead, they occupy defined niches that facilitate efficient communication.

Cytotoxic T lymphocytes (CTLs), for example, are typically positioned in central regions of the lymph node, where they interact with type 1 dendritic cells (cDC1s) that present antigen and initiate activation. As explained by the study authors, “cytotoxic T lymphocytes are typically found in central regions of the lymph node, where they colocalize and interact with specialized cells called type 1 dendritic cells that present danger signals to them.”

While the importance of this organization has long been appreciated, the mechanisms guiding immune cells to the correct locations have remained incompletely understood.

A fibroblast niche organizes T cell positioning

To address this question, the Lausanne team focused on fibroblasts, a class of stromal cells that form the structural backbone of lymphoid tissues. Using mouse models and human lymph node samples, they identified a distinct subset of fibroblasts located in the central compartment.

These fibroblasts are characterized by expression of MAdCAM1 and by their production of high levels of the chemokine CCL19. This signaling molecule acts as an attractant that guides cytotoxic T cells into proximity with dendritic cells, enabling productive immune interactions. As the researchers note, CCL19 “acts as an ‘attractant signal’ for cytotoxic T lymphocytes, bringing them into physical contact with type 1 dendritic cells.”

By shaping this spatial organization, the fibroblast subset creates a functional niche that promotes T cell activation. When this system was disrupted, cytotoxic T cells failed to position correctly and showed impaired differentiation into memory T cells, highlighting the importance of tissue architecture for long-term immunity.

Notch signaling maintains the stromal network

The researchers also identified the molecular pathway that sustains this fibroblast population. A signaling axis involving Notch2 and its downstream mediator RBPj was found to be essential for maintaining the identity and activity of the CCL19-producing fibroblasts.

In addition, Jagged-1, a ligand produced primarily by dendritic cells, appears to initiate or reinforce this signaling loop. This suggests a feedback mechanism in which immune cells and stromal cells cooperate to maintain the lymph node architecture.

According to the scientists, this pathway must remain active throughout life. When Notch2 signaling was disrupted in fibroblasts, the structural integrity of the niche was lost, leading to defective T cell responses and reduced formation of memory cells.

A conserved mechanism across immune tissues

Although the study focused on lymph nodes, the same organizational principles appear to extend to other immune organs. The researchers observed similar regulation of CCL19 production in the spleen and Peyer’s patches, which are involved in blood filtration and intestinal immunity.

Comparable fibroblast populations were also identified in human lymph nodes, suggesting that this mechanism is conserved across species and relevant to human immune function.

Implications for immunotherapy and vaccines

The findings add to a growing body of evidence that stromal cells play active roles in shaping immune responses. Rather than acting as passive scaffolds, fibroblasts help define where immune interactions occur and how effectively they proceed.

This has important implications for disease. In cancer, for example, ineffective T cell responses may result not only from intrinsic immune dysfunction but also from disrupted tissue organization that prevents optimal cell–cell interactions.

In vaccination, enhancing the formation or function of such stromal niches could improve immune activation and the development of long-lasting memory responses.

Looking ahead

The identification of a fibroblast-driven mechanism for organizing immune cell positioning provides a new foundation for understanding how immune responses are initiated and maintained.

Future research will be needed to explore whether targeting stromal signaling pathways, such as Notch2, can be used to modulate immune responses in therapeutic settings. While such approaches remain speculative, they highlight the potential of integrating tissue architecture into the design of next-generation immunotherapies.

“Overall, these findings deepen our understanding of the organization of the immune system and how effective T cell responses against infections and cancer are initiated,” said Sanjiv Luther, PhD, senior author of the study. “In the future, this knowledge could help improve vaccine design and clarify why immune defenses sometimes fail against certain pathogens or tumors.”

The post Fibroblast Subset Directs Immune Cell Positioning in Lymph Nodes appeared first on Inside Precision Medicine.

Cross-reactive anti-prophage antibodies and bacterial heteroresistance implicated in phage therapeutic failure

Nature Medicine, Published online: 24 April 2026; doi:10.1038/s41591-026-04301-0

A 22-year-old patient with cystic fibrosis and chronic, drug-resistant Bordetella bronchialis infection received compassionate-use phage therapy. Serum samples revealed that pre-existing antiphage immunity existed before treatment, indicating that future studies must evaluate antiphage immunity across the entire treatment regimen.

Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learned

Since I was 7, my goal has been to become a doctor. But life had other plans. I grew up in a blue-collar family in Levittown, N.Y., in the 1950s and ’60s, so it often felt like the world ended in Jersey. When I landed in Lansing, Mich., to attend Michigan State, I expected the Rocky Mountains to be visible. I ended up getting a degree in nursing, but I always had another goal: to become an M.D.

This year, at the age of nearly 73, my dream will finally come true. Soon after, I will start my residency in family medicine. My perspective on medical school and medicine is unique not only because I attended late in life, but because it came after more than 40 years as a nurse practitioner.

Read the rest…